Condition

Carcinoma, Non-Small-Cell Lung clinical trials and research

• 61Clinical trials
• 51Countries

Newest Carcinoma, Non-Small-Cell Lung clinical trials

All recruiting trials (61)

• Amivantamab with Lazertinib or Chemotherapy before surgery in EGFR-mutated NSCLC

  This study tests whether giving amivantamab together with lazertinib or with carboplatin and pemetrexed before surgery can slow or stop tumor growth in people with resectable EGFR-mutated NSCLC.

  Recruiting at 27 sites Phase 2 Janssen Research & Development, LLC · Duarte, California and 26 other locations · NCT07586202

• Multidisciplinary treatment planning for older people with lung cancer

  We will test a team-based approach that uses geriatric assessments to create personalized treatment plans for people aged 60–90 with newly diagnosed lung cancer to see if it improves 3-year progression-free survival compared with past patients.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07509333

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• Intratumoral injection of N17350 in advanced solid tumors

  Aims to see if injected N17350 can shrink or control tumors in adults with advanced solid cancers who have few other options.

  Recruiting at 7 sites Phase 1/2 Onchilles Pharma Inc · Los Angeles, California and 8 other locations · NCT07339176

• Clinical outcomes of amivantamab-based treatment for advanced EGFR-mutated non-small cell lung cancer in everyday care.

  This project will see how amivantamab-containing treatments work for people with advanced non-small cell lung cancer who have common EGFR mutations.

  Recruiting at 90 sites Janssen Research & Development, LLC · Graz and 89 other locations · NCT07230691

• PF-08634404 combined with other cancer medicines for advanced non-small cell lung cancer

  This will test whether PF-08634404 given with other cancer medicines is safe and can help adults with advanced or metastatic non-small cell lung cancer.

  Recruiting at 85 sites Phase 1/2 Pfizer · Fayetteville, Arkansas and 103 other locations · NCT07227298

• Amivantamab plus olomorasib for metastatic KRAS G12C non-small cell lung cancer

  This trial tests whether combining amivantamab and olomorasib can slow tumor growth in people with metastatic non-small cell lung cancer that has a KRAS G12C mutation after platinum chemotherapy and PD‑L1 immunotherapy.

  Recruiting at 12 sites Phase 1/2 Janssen Research & Development, LLC · New York, New York and 11 other locations · NCT07227025

• PF-08634404 plus chemotherapy versus pembrolizumab-based chemotherapy for advanced non-small cell lung cancer

  This will test whether PF-08634404 combined with chemotherapy works better than pembrolizumab plus chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer who have not received prior treatment for their advanced disease.

  Recruiting at 464 sites Phase 3 Pfizer · Bullhead City, Arizona and 483 other locations · NCT07222566

• ALG Lung Cancer Registry (SAFRO2202)

  This registry will collect medical information from adults in Algeria who have been diagnosed with any type of lung cancer to see patterns in diagnosis, treatment, and outcomes.

  Recruiting at 21 sites Société Algérienne de Formation et de Recherche en Oncologie · Algiers, Algiers Province and 20 other locations · NCT07161882

• Ubamatamab with or without REGN7075 for adults with advanced or metastatic non-small cell lung cancer

  This trial will try ubamatamab alone and with REGN7075 in adults with advanced or metastatic non-small cell lung cancer to see if they control the cancer and will try sarilumab to manage immune-related side effects.

  Recruiting at 18 sites Phase 2 Regeneron Pharmaceuticals · Birmingham, Alabama and 17 other locations · NCT07154290

• First-in-human imaging test with Ga-DWJ155 in advanced breast cancer and NSCLC

  This early-phase study tests a radioactive imaging agent, 68Ga-DWJ155, to see how it distributes in the body and how well it images tumors in adults with HR+/HER2-, HER2+, or NSCLC adenocarcinoma.

  Recruiting Phase 1 Novartis · Groningen, Provincie Groningen · NCT07117214

• PF-08046876 for people with advanced solid tumors

  This trial tests a new antibody–drug conjugate called PF-08046876 given by IV in adults with advanced bladder, lung, head and neck, esophageal, or pancreatic cancers to see if it is safe and how it affects tumors.

  Recruiting at 30 sites Phase 1 Pfizer · Duarte, California and 30 other locations · NCT07090499

• LY4175408 for selected advanced lung, endometrial, and triple‑negative breast cancers

  This trial tests an experimental drug called LY4175408 to see if it is safe and works for people with advanced or metastatic non‑small cell or small cell lung cancer, endometrial cancer, or triple‑negative breast cancer.

  Recruiting at 24 sites Phase 1 Eli Lilly and Company · Stanford, California and 26 other locations · NCT07046923

• THIO plus cemiplimab versus chemotherapy for third-line advanced non-small cell lung cancer

  This trial tries giving THIO followed by the PD‑1 drug cemiplimab versus standard chemotherapy in adults with advanced or metastatic non-small cell lung cancer who have already had two prior treatments including an immune checkpoint inhibitor and platinum chemotherapy.

  Recruiting at 15 sites Phase 3 Maia Biotechnology · Poznan and 14 other locations · NCT06908304

• Combining Olomorasib with Standard Treatments for KRAS G12C-mutant Lung Cancer

  This study is testing if adding olomorasib to standard treatments can help people with KRAS G12C-mutant lung cancer do better than with the usual care alone.

  Recruiting at 349 sites Phase 3 Eli Lilly and Company · Huntsville, Alabama and 367 other locations · NCT06890598

• Combining adagrasib, pembrolizumab, and chemotherapy for lung cancer with a specific mutation

  This study is testing a new treatment combining adagrasib, pembrolizumab, and chemotherapy to see if it helps people with a specific type of lung cancer that has a KRAS G12C mutation.

  Recruiting at 303 sites Phase 3 Mirati Therapeutics Inc. · Birmingham, Alabama and 316 other locations · NCT06875310

• Comparing rilvegostomig and pembrolizumab for treating advanced lung cancer

  This study is testing whether a new drug called rilvegostomig works better than pembrolizumab for treating advanced lung cancer in patients whose tumors have a specific marker.

  Recruiting at 247 sites Phase 3 AstraZeneca · La Mesa, California and 303 other locations · NCT06868277

• Evaluating outcomes of ALK-positive lung cancer patients treated with Alectinib after surgery

  This study is testing if Alectinib can help adults with ALK-positive lung cancer feel better after their surgery.

  Recruiting at 43 sites Hoffmann-La Roche · Zhanjiang, Guangdong and 43 other locations · NCT06862869

• Evaluating BMS-986504 for advanced lung cancer with specific genetic deletion

  This study is testing a new drug called BMS-986504 to see if it can help people with advanced lung cancer who have a specific genetic change and have not responded to previous treatments.

  Recruiting at 65 sites Phase 2 Bristol-Myers Squibb · Anchorage, Alaska and 66 other locations · NCT06855771

• Combining Sigvotatug Vedotin and Pembrolizumab for Non-Small Cell Lung Cancer

  This study is testing a new combination of two treatments, Sigvotatug Vedotin and pembrolizumab, to see if it helps people with advanced non-small cell lung cancer feel better compared to just using pembrolizumab alone.

  Recruiting at 355 sites Phase 3 Pfizer · Fullerton, California and 388 other locations · NCT06758401

• Afatinib plus chemotherapy to convert unresectable EGFR‑mutant stage III NSCLC into resectable disease.

  This trial will see if afatinib combined with chemotherapy can shrink unresectable, EGFR‑sensitive mutation positive stage III non‑small cell lung cancer enough to allow surgery.

  Recruiting Phase 2 Shandong Public Health Clinical Center · Jinan, Shangdong · NCT06709859

• Evaluating AST-201 for GPC3-positive advanced solid tumors

  This study is testing a new treatment called AST-201 to see if it can help people with advanced solid tumors that have a specific marker called GPC3.

  Recruiting at 4 sites Phase 1 Aptamer Sciences, Inc. · Goyang-si, Gyeonggi-do and 3 other locations · NCT06687941

• Combining JNJ-90301900 with chemotherapy and radiation for advanced lung cancer

  This study is testing if adding a new drug called JNJ-90301900 to standard chemotherapy and radiation can help people with advanced lung cancer respond better to treatment.

  Recruiting at 44 sites Phase 2 Johnson & Johnson Enterprise Innovation Inc. · La Jolla, California and 44 other locations · NCT06667908

• Combining Amivantamab with Lazertinib or Chemotherapy for Advanced Lung Cancer

  This study tests if a new combination of amivantamab with lazertinib or chemotherapy can help people with advanced lung cancer that has certain genetic changes.

  Recruiting at 68 sites Phase 2 Janssen Research & Development, LLC · Daphne, Alabama and 204 other locations · NCT06667076

• Adding a CyberKnife boost after chemoradiation for locally advanced non-small-cell lung cancer

  This trial will try giving a targeted CyberKnife radiation boost after standard platinum-based induction and concurrent chemoradiation to see if it improves outcomes for adults with unresectable stage III non-small-cell lung cancer.

  Recruiting Phase 2 Centre Antoine Lacassagne · Nice · NCT06627738

• Comparing Cemiplimab with chemotherapy and radiation for lung cancer treatment

  This study is testing whether combining a drug called Cemiplimab with chemotherapy or with a type of radiation therapy helps people with certain stages of lung cancer do better before surgery.

  Recruiting Phase 2 Weill Medical College of Cornell University · New York, New York · NCT06623656

• Using 68Ga-grazytracer PET imaging to evaluate immunotherapy in lung cancer

  This study is testing if a special type of PET imaging can help doctors see how well immunotherapy is working for patients with stage III non-small cell lung cancer.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06623487

• Combining pembrolizumab with intismeran autogene for non-small cell lung cancer treatment

  This study is testing if a new combination of a gene therapy and a cancer drug can help people with non-small cell lung cancer stay cancer-free after surgery.

  Recruiting at 234 sites Phase 3 Merck Sharp & Dohme LLC · Gilbert, Arizona and 245 other locations · NCT06623422

• Using honokiol to prevent lung cancer recurrence before surgery

  This study is testing if taking honokiol, a dietary supplement, can safely help prevent lung cancer from coming back in patients with early-stage non-small cell lung cancer before their surgery.

  Recruiting Phase 1 The Methodist Hospital Research Institute · Houston, Texas · NCT06566443

• Testing DM005 for advanced solid tumors

  This study is testing a new treatment called DM005 to see if it can help people with advanced solid tumors feel better and improve their health.

  Recruiting at 6 sites Phase 1/2 Doma Biopharmaceutical（Suzhou）Co., Ltd. · Detroit, Michigan and 5 other locations · NCT06515990

• Higher-dose proton radiation for stage III non-small-cell lung cancer

  This pilot tests whether giving a higher dose of proton radiation together with chemo and planned immunotherapy is safe and tolerable for adults with stage III non-small-cell lung cancer.

  Recruiting University Medical Center Groningen · Groningen · NCT06484491

• Ongoing collection of blood and tumor samples from people with lung cancer

  Collect and store blood and tumor samples over time from adults with newly diagnosed or metastatic lung cancer to build a real-world biobank for research.

  Recruiting Nantes University Hospital · Angers and 3 other locations · NCT06481813

• Treatment for lung cancer patients who had surgery but are not disease-free

  This study is testing two new immunotherapy treatments for lung cancer patients who have had surgery but still have some disease to see if they can help them stay cancer-free longer.

  Recruiting at 31 sites Phase 3 Fundación GECP · Alicante, Alicante and 31 other locations · NCT06431633

• Evaluating LY4170156 for advanced solid tumors

  This study is testing a new drug called LY4170156 to see if it is safe and effective for people with advanced solid tumors like ovarian and lung cancers.

  Recruiting at 24 sites Phase 1 Eli Lilly and Company · Scottsdale, Arizona and 24 other locations · NCT06400472

• Testing UCB4594 for advanced cancer treatment

  This study is testing a new drug called UCB4594 to see if it can help treat advanced cancer by targeting a specific protein on cancer cells.

  Recruiting at 3 sites Phase 1/2 Cancer Research UK · London and 3 other locations · NCT06380816

• Using Toripalimab before surgery for advanced lung cancer with specific mutations

  This study is testing if giving a new immunotherapy called Toripalimab before surgery can help people with advanced lung cancer who have specific genetic mutations feel better and improve their chances of recovery.

  Recruiting at 2 sites Phase 2 Ruijin Hospital · Guangzhou, Guangdong and 1 other locations · NCT06269211

• Testing a new drug for adults with advanced solid tumors

  This study is testing a new drug for adults with advanced solid tumors that haven't responded to other treatments to see if it can help them.

  Recruiting at 43 sites Phase 1 Seagen Inc. · Phoenix, Arizona and 47 other locations · NCT06131840

• Combining Olomorasib and Pembrolizumab for Advanced KRAS G12C-Mutant Lung Cancer

  This study is testing if a new drug combined with Pembrolizumab can help people with advanced lung cancer that has a specific genetic mutation feel better and live longer compared to standard treatments.

  Recruiting at 413 sites Phase 3 Eli Lilly and Company · Huntsville, Alabama and 414 other locations · NCT06119581

• Evaluating a new imaging technique for lung cancer diagnosis

  This study is testing a new imaging technique during lung procedures to see if it helps doctors diagnose lung cancer more accurately in patients with suspicious lung lesions.

  Recruiting at 5 sites Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · New York, New York and 4 other locations · NCT06079970

• Combining Sugemalimab with Chemotherapy for Advanced Lung Cancer

  This study is testing if combining a new drug called Sugemalimab with chemotherapy can help people with advanced lung cancer that can't be surgically removed feel better and improve their chances of recovery.

  Recruiting Phase 2 Hunan Cancer Hospital · Changsha · NCT05940532

• Registry for genomic medicine in lung cancer in Germany

  This study is collecting information from lung cancer patients in Germany to see how their treatment and outcomes can be improved.

  Recruiting University of Cologne · Cologne · NCT05934032

• Observational study on biomarker testing in lung cancer patients

  This study looks at how testing for specific markers in lung cancer can help patients get better treatment options and improve their care experience.

  Recruiting at 9 sites US Oncology Research · Daphne, Alabama and 16 other locations · NCT05885698

• Pemetrexed injected into the spinal fluid for EGFR‑mutant lung cancer that has spread to the leptomeninges.

  This tests whether giving pemetrexed directly into the spinal fluid helps people with EGFR‑mutant non‑small cell lung cancer whose cancer has spread to the leptomeninges after osimertinib has stopped working.

  Recruiting Phase 2 Taipei Veterans General Hospital, Taiwan · Taipei, Taiwan · NCT05805631

• Combination of vemurafenib and cobimetinib for treating BRAF positive cancers

  This study is testing if the combination of vemurafenib and cobimetinib can help adults with different types of cancers that have a specific BRAF mutation.

  Recruiting at 16 sites Phase 2/3 Cancer Research UK · Belfast and 15 other locations · NCT05768178

• Comparing standard and adjusted doses of alectinib for lung cancer treatment

  This study is testing if adjusting the dose of alectinib based on blood levels can help people with ALK positive lung cancer live longer without their disease getting worse compared to the standard dose.

  Recruiting at 7 sites Phase 4 University Medical Center Groningen · Villejuif, Val-de-Marne and 7 other locations · NCT05525338

• Evaluating amivantamab for advanced non-small cell lung cancer

  This study is testing if a new treatment combining amivantamab and another drug can help people with advanced non-small cell lung cancer, especially those with certain genetic mutations.

  Recruiting at 82 sites Phase 2 Janssen Research & Development, LLC · La Jolla, California and 109 other locations · NCT05498428

• Evaluating Ensartinib for Advanced ALK-positive Lung Cancer

  This study is testing if a daily pill called Ensartinib can help people with advanced ALK-positive lung cancer feel better and live longer.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT05498064

• Combining QL1706 with chemotherapy for lung cancer treatment after surgery

  This study is testing if adding a new treatment called QL1706 to standard chemotherapy helps people with stage II-IIIB lung cancer feel better after surgery.

  Recruiting Phase 3 Qilu Pharmaceutical Co., Ltd. · Shanghai · NCT05487391

• LP-300 with Carboplatin and Pemetrexed for Never Smokers with Advanced Lung Adenocarcinoma

  This study is testing if adding a new drug called LP-300 to standard chemotherapy can help people who have never smoked and have advanced lung adenocarcinoma live longer and feel better.

  Recruiting at 10 sites Phase 2 Lantern Pharma Inc. · Beverly Hills, California and 15 other locations · NCT05456256

• Testing a new drug for advanced solid tumors

  This study is testing a new drug for people with advanced solid tumors, like lung and head and neck cancers, to see if it works better when combined with another treatment after other options have failed.

  Recruiting at 62 sites Phase 1 Seagen Inc. · Birmingham, Alabama and 61 other locations · NCT05208762

• Induction immunotherapy for advanced non-small cell lung cancer patients without curative options

  This study is testing if a new type of immunotherapy can help people with advanced non-small cell lung cancer who can't have surgery or other curative treatments.

  Recruiting Klinikum Esslingen · Esslingen am Neckar · NCT04926584

• Supportive care model for patients with advanced lung cancer

  This study is testing a new supportive care program for people with advanced lung cancer to see if it helps them feel less stressed and more confident about managing their condition compared to standard care.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT04900935

• Evaluating lymph node dissection in early-stage lung adenocarcinoma

  This study is testing whether skipping lymph node surgery can still help people with early-stage lung cancer live longer without their disease coming back.

  Recruiting Fudan University · Shanghai · NCT04527419

• Combining durvalumab and tremelimumab with chemotherapy for HIV-infected lung cancer patients

  This study is testing if a combination of two immune treatments with chemotherapy can help people with stage IV lung cancer who are also living with HIV.

  Recruiting at 4 sites Phase 2 Georgetown University · Washington D.C., District of Columbia and 3 other locations · NCT04499053

• Combining gene therapy with osimertinib for advanced lung cancer patients

  This study is testing a new gene therapy combined with osimertinib to see if it can help people with advanced lung cancer who haven't responded to their current treatment.

  Recruiting at 8 sites Phase 1/2 Genprex, Inc. · Los Angeles, California and 9 other locations · NCT04486833

• Testing a new drug for advanced solid tumors

  This study is testing a new drug called sigvotatug vedotin to see if it can safely help people with advanced solid tumors, both on its own and with other treatments.

  Recruiting at 145 sites Phase 1 Seagen Inc. · Anchorage, Alaska and 157 other locations · NCT04389632

• Investigating Pembrolizumab Alone or With Chemotherapy for Non-Small Cell Lung Cancer

  This study is testing whether the drug pembrolizumab, alone or with chemotherapy, can help people with non-small cell lung cancer.

  Recruiting at 17 sites Merck Sharp & Dohme LLC · Gilbert, Arizona and 47 other locations · NCT04165798

• Efficacy and safety of pembrolizumab with or without chemotherapy for advanced lung cancer

  This study is testing if adding pembrolizumab to chemotherapy helps people with advanced lung cancer feel better and live longer compared to using pembrolizumab alone.

  Recruiting at 16 sites Phase 1/2 Merck Sharp & Dohme LLC · Gilbert, Arizona and 46 other locations · NCT04165070

• Assessing the impact of Tyrosine Kinase Inhibitors on bone metastasis in lung cancer patients

  This study is testing if a new type of cancer drug called Tyrosine Kinase Inhibitors can help lung cancer patients with bone metastases feel better compared to those getting standard treatments.

  Recruiting at 2 sites University of Colorado, Denver · Aurora, Colorado and 1 other locations · NCT03958565

• Comparing video-assisted surgery to traditional surgery for early-stage lung cancer

  This study is testing if a less invasive video-assisted surgery is just as effective as traditional surgery for people with early-stage lung cancer.

  Recruiting Fudan University · Shanghai · NCT03786003

• Characterizing genetic profiles in advanced non-small cell lung cancer using liquid biopsies

  This study is testing whether a simple blood test can help find genetic changes in patients with advanced lung cancer to guide their treatment options.

  Recruiting Centre Leon Berard · Annecy and 7 other locations · NCT02511288

Related topics

Quick answers

How many Carcinoma, Non-Small-Cell Lung clinical trials are recruiting right now?

61, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 51 countries. The most sites are in United States (33 trials), China (26 trials), Spain (23 trials), France (21 trials), United Kingdom (18 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 14, Phase 3: 10, Phase 1: 9, Phase 1/2: 7. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →